|
hepatocellular carcinoma |
30 |
|
hbv |
25 |
|
chronic hepatitis b |
24 |
|
hepatitis b virus |
24 |
|
hepatitis b |
21 |
|
medical sciences |
21 |
|
adult |
20 |
|
female |
20 |
|
humans |
20 |
|
male |
20 |
|
hbsag |
19 |
|
adolescent |
17 |
|
antiviral |
17 |
|
entecavir |
17 |
|
middle aged |
17 |
|
aged |
16 |
|
antiviral therapy |
16 |
|
gastroenterology |
16 |
|
cirrhosis |
15 |
|
hepatitis b surface antigen |
15 |
|
nafld |
15 |
|
functional cure |
14 |
|
liver fibrosis |
14 |
|
mutation |
14 |
|
aged, 80 and over |
13 |
|
dna, viral - blood |
13 |
|
flare |
13 |
|
follow-up studies |
13 |
|
hcv |
13 |
|
liver cancer |
13 |
|
liver stiffness |
13 |
|
chronic viral hepatitis |
12 |
|
dna, viral - analysis |
12 |
|
genotype |
12 |
|
hepatitis b virus - genetics |
12 |
|
nucleos(t)ide analogue |
12 |
|
nucleoside analogues |
12 |
|
risk factors |
12 |
|
virus replication |
12 |
|
age |
11 |
|
alanine aminotransferase |
11 |
|
controlled attenuation parameter |
11 |
|
extracellular vesicles |
11 |
|
fibrosis |
11 |
|
hepatitis b core-related antigen |
11 |
|
liver cirrhosis - complications - diagnosis |
11 |
|
longitudinal studies |
11 |
|
nidogen 1 |
11 |
|
nucleoside analogue |
11 |
|
predictive value of tests |
11 |
|
pre‐metastatic niche |
11 |
|
tumor necrosis factor receptor 1 |
11 |
|
alanine transaminase - blood |
10 |
|
biomarker |
10 |
|
carcinoma, hepatocellular - etiology |
10 |
|
carcinoma, hepatocellular - virology |
10 |
|
child |
10 |
|
child, preschool |
10 |
|
hepatitis b antibodies - blood |
10 |
|
hepatitis b e antigens - blood |
10 |
|
hong kong - epidemiology |
10 |
|
infant |
10 |
|
intercellular communication |
10 |
|
liver - pathology - virology |
10 |
|
liver cirrhosis - etiology |
10 |
|
liver neoplasms - virology |
10 |
|
m2bpgi |
10 |
|
models, biological |
10 |
|
neutralizing antibody |
10 |
|
proteomics |
10 |
|
surface antigen |
10 |
|
tumor microenvironment |
10 |
|
vaccination |
10 |
|
antiviral agents - therapeutic use |
9 |
|
apoptosis |
9 |
|
asian continental ancestry group - statistics & numerical data |
9 |
|
carrier state |
9 |
|
fatty liver disease |
9 |
|
hav |
9 |
|
hbeag |
9 |
|
hepatitis b surface antigens - immunology |
9 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
9 |
|
hepatitis b, chronic - pathology |
9 |
|
hev |
9 |
|
immigration |
9 |
|
liver cirrhosis - pathology - virology |
9 |
|
liver neoplasms - etiology |
9 |
|
mortality |
9 |
|
nash |
9 |
|
non-viral liver disease |
9 |
|
pre-s deletions |
9 |
|
prognosis |
9 |
|
reproducibility of results |
9 |
|
seroclearance |
9 |
|
tenofovir |
9 |
|
tumorigenesis |
9 |
|
alanine transaminase - metabolism |
8 |
|
cccdna |
8 |
|
elasticity imaging techniques |
8 |
|
elasticity imaging techniques - methods |
8 |
|
galectin-1 |
8 |
|
hbcrag |
8 |
|
hbv dna |
8 |
|
hepatitis b e antigens - metabolism |
8 |
|
hepatitis b virus - genetics - immunology |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
hepatitis b, chronic - drug therapy - virology |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
immune response |
8 |
|
lamivudine - therapeutic use |
8 |
|
liver failure - pathology - virology |
8 |
|
mir-22 |
8 |
|
nephrotoxicity |
8 |
|
otx008 |
8 |
|
protein precursors - genetics |
8 |
|
reverse transcriptase inhibitors - therapeutic use |
8 |
|
serology |
8 |
|
therapeutics |
8 |
|
accuracy |
7 |
|
alanine aminotransferase blood level |
7 |
|
cap |
7 |
|
diagnostic test accuracy study |
7 |
|
disease progression |
7 |
|
disease severity |
7 |
|
drug response |
7 |
|
elastography |
7 |
|
endocrinology |
7 |
|
etv |
7 |
|
hepatitis b core antigens - genetics |
7 |
|
hepatitis b virus - classification - genetics |
7 |
|
hepatitis b virus - drug effects - genetics |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b virus infection |
7 |
|
hepatitis b, chronic - blood - drug therapy - virology |
7 |
|
hepatitis b, chronic - complications |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
hepatitis c |
7 |
|
itraq |
7 |
|
liver - chemistry - pathology |
7 |
|
liver - pathology |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
metabolic |
7 |
|
metabolic syndrome |
7 |
|
mutation - genetics |
7 |
|
natural history |
7 |
|
obesity |
7 |
|
promoter regions, genetic |
7 |
|
risk factor |
7 |
|
transient elastography |
7 |
|
treatment outcome |
7 |
|
viral load |
7 |
|
young adult |
7 |
|
adefovir |
6 |
|
age factors |
6 |
|
anti-hbc |
6 |
|
anti-hbs |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
blood donors - statistics and numerical data |
6 |
|
carcinoma, hepatocellular - diagnosis - epidemiology |
6 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
chronic hepatitis b virus |
6 |
|
cigarette smoking |
6 |
|
circular dna |
6 |
|
covalently closed circular dna |
6 |
|
dna methylation |
6 |
|
drug resistance, viral |
6 |
|
drug therapy, combination |
6 |
|
enhancer elements (genetics) - genetics |
6 |
|
epidemiology |
6 |
|
fatty liver |
6 |
|
fibroscan |
6 |
|
full-length genome sequencing |
6 |
|
gastric cancer |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
gitr |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
hbeag seroconversion |
6 |
|
hcc |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b surface antigens - blood - immunology |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - complications - genetics |
6 |
|
hepatitis b, chronic - blood - complications - immunology - pathology - virology |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
host-pathogen interactions |
6 |
|
hs-hbsag |
6 |
|
immune exhaustion |
6 |
|
inflammation |
6 |
|
interleukin‐27 |
6 |
|
intrahepatic hbv dna |
6 |
|
kinetics |
6 |
|
lamivudine |
6 |
|
lamivudine - adverse effects - therapeutic use |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
liver biopsy |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver neoplasms - diagnosis - epidemiology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
longitudinal |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
mass screening - methods |
6 |
|
na therapy |
6 |
|
non-alcoholic fatty liver disease |
6 |
|
pd-1 |
6 |
|
prediction |
6 |
|
prevalence |
6 |
|
promoter regions (genetics) - genetics |
6 |
|
promoter regions, genetic - genetics |
6 |
|
proportional hazards models |
6 |
|
prospective studies |
6 |
|
quasispecies |
6 |
|
regulatory t cells |
6 |
|
response to therapy |
6 |
|
seroepidemiologic studies |
6 |
|
sex factors |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
t regulatory cells |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
time factors |
6 |
|
vcte |
6 |
|
viral core proteins - genetics |
6 |
|
viral hepatitis |
6 |
|
viral integration |
6 |
|
virus dna |
6 |
|
wfa + -m2bp |
6 |
|
alanine transaminase - analysis |
5 |
|
alkaline phosphatase - blood |
5 |
|
alpha-fetoproteins - analysis |
5 |
|
anaemia |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
antiviral agents - adverse effects - therapeutic use |
5 |
|
antiviral treatment |
5 |
|
asian continental ancestry group |
5 |
|
aspartate aminotransferases - blood |
5 |
|
bilirubin - blood |
5 |
|
carcinoma, hepatocellular - diagnosis - pathology |
5 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
5 |
|
case-control studies |
5 |
|
china |
5 |
|
core antigen |
5 |
|
core protein |
5 |
|
core protein allosteric modulator |
5 |
|
cure |
5 |
|
customized therapies |
5 |
|
ddpcr |
5 |
|
deep sequencing |
5 |
|
deleterious mutations |
5 |
|
dna, circular - analysis - isolation & purification |
5 |
|
dna, viral - analysis - isolation & purification |
5 |
|
dna, viral - genetics |
5 |
|
dna-directed dna polymerase - genetics |
5 |
|
drugs, chinese herbal - adverse effects |
5 |
|
dyslipidemia |
5 |
|
fibrosis regression |
5 |
|
finite |
5 |
|
freezing |
5 |
|
gamma-glutamyltransferase - blood |
5 |
|
gene deletion |
5 |
|
gene expression regulation, viral |
5 |
|
gene silencing |
5 |
|
genetic predisposition to disease |
5 |
|
globulins - analysis |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
hbx |
5 |
|
hbx protein |
5 |
|
hepacivirus - genetics |
5 |
|
hepatitic decompensation |
5 |
|
hepatitis b - drug therapy - genetics - physiopathology - virology |
5 |
|
hepatitis b core antigens - genetics - immunology |
5 |
|
hepatitis b e antigen seroconversion |
5 |
|
hepatitis b e antigens - biosynthesis - genetics - immunology |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b surface antigens - metabolism |
5 |
|
hepatitis b virus - chemistry - classification - genetics |
5 |
|
hepatitis b virus - drug effects - enzymology - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b virus replication |
5 |
|
hepatitis b, chronic - blood - drug therapy |
5 |
|
hepatitis b, chronic - blood - pathology - virology |
5 |
|
hepatitis b, chronic - complications - genetics - virology |
5 |
|
hepatitis b, chronic - complications - mortality - pathology |
5 |
|
hepatitis b, chronic - complications - virology |
5 |
|
hepatitis b, chronic - drug therapy |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatitis b, chronic - genetics - immunology - virology |
5 |
|
hepatitis c virus |
5 |
|
hepatitis c, chronic - drug therapy - virology |
5 |
|
herbal medicine |
5 |
|
interferon-alpha - therapeutic use |
5 |
|
interferon-gamma - biosynthesis - immunology |
5 |
|
interleukin-10 - immunology |
5 |
|
interleukin-2 - immunology |
5 |
|
interleukin-4 - immunology |
5 |
|
interleukin-5 - immunology |
5 |
|
intrahepatic hepatitis b virus dna |
5 |
|
lamivudine - administration & dosage - therapeutic use |
5 |
|
linearized hbsag |
5 |
|
liver |
5 |
|
liver - metabolism |
5 |
|
liver - virology |
5 |
|
liver biochemistry |
5 |
|
liver cirrhosis |
5 |
|
liver cirrhosis - diagnosis |
5 |
|
liver diseases - etiology |
5 |
|
liver histology |
5 |
|
liver neoplasms - epidemiology - genetics - virology |
5 |
|
liver steatosis |
5 |
|
liver transplantation |
5 |
|
lymphocyte activation |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
medicine, chinese traditional - adverse effects |
5 |
|
microrna |
5 |
|
mitosis |
5 |
|
multivariate analysis |
5 |
|
nucleocapsid |
5 |
|
nucleos/tide analogues |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
nucleotide analogue |
5 |
|
obese mice |
5 |
|
occult hepatitis b infection |
5 |
|
pcr |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
polymorphism, genetic |
5 |
|
precore mutation |
5 |
|
promoter regions (genetics) |
5 |
|
protein stability |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
qpcr |
5 |
|
quantitative |
5 |
|
recombinant proteins |
5 |
|
resistance |
5 |
|
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
|
reverse transcriptase polymerase chain reaction |
5 |
|
ribavirin |
5 |
|
ribavirin - therapeutic use |
5 |
|
rna, messenger - analysis - isolation & purification |
5 |
|
rna, viral - analysis - isolation & purification |
5 |
|
roc curve |
5 |
|
serologic tests |
5 |
|
severe hepatitis b exacerbation |
5 |
|
single polynucleotide polymorphisms |
5 |
|
sirt1 |
5 |
|
sirtuin |
5 |
|
specimen handling - methods |
5 |
|
statistics, nonparametric |
5 |
|
stopping |
5 |
|
survival analysis |
5 |
|
sustained virologic response |
5 |
|
t helper response |
5 |
|
targeted sequencing |
5 |
|
th1 cells - immunology |
5 |
|
th2 cells - immunology |
5 |
|
transcription |
5 |
|
translation |
5 |
|
treatment guidelines |
5 |
|
tumor |
5 |
|
viraemia |
5 |
|
viral dna integration |
5 |
|
viral suppression |
5 |
|
virology |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
ymdd mutation |
5 |
|
actins - genetics |
4 |
|
adenine - analogs & derivatives - therapeutic use |
4 |
|
age distribution |
4 |
|
aging |
4 |
|
amino acid motifs - drug effects - genetics |
4 |
|
anti-hepatitis b core total antibodies |
4 |
|
anti-hiv agents - therapeutic use |
4 |
|
antineoplastic agents - administration & dosage |
4 |
|
antiviral agents - pharmacology - therapeutic use |
4 |
|
asian continental ancestry group - ethnology |
4 |
|
asian continental ancestry group - genetics |
4 |
|
aspartic acid - drug effects - genetics |
4 |
|
bacteroides |
4 |
|
bile acid |
4 |
|
biological markers - blood |
4 |
|
biopsy - methods |
4 |
|
blood - virology |
4 |
|
blood transfusion - adverse effects |
4 |
|
carcinoma, hepatocellular - diagnosis - virology |
4 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
4 |
|
care cascade |
4 |
|
chemoembolization, therapeutic - methods |
4 |
|
china - ethnology |
4 |
|
cisplatin - administration & dosage |
4 |
|
cohort studies |
4 |
|
contrast media - administration & dosage |
4 |
|
core promoter mutation |
4 |
|
core-promoter mutation |
4 |
|
cross-sectional studies |
4 |
|
cytokines |
4 |
|
dna methylation - immunology |
4 |
|
dna, circular - analysis |
4 |
|
dna, circular - blood - drug effects |
4 |
|
dna, viral - blood - drug effects |
4 |
|
dna, viral - blood - isolation & purification |
4 |
|
dna, viral - genetics - isolation and purification |
4 |
|
dose-response relationship, immunologic |
4 |
|
drug resistance, multiple, viral - genetics |
4 |
|
drug resistance, viral - genetics |
4 |
|
e-cadherin |
4 |
|
elasticity |
4 |
|
enzyme-linked immunosorbent assay - methods |
4 |
|
estrogen |
4 |
|
gastritis/genetics - immunology/prevention & control |
4 |
|
gender difference |
4 |
|
gene products, pol - genetics |
4 |
|
guanine - analogs & derivatives - therapeutic use |
4 |
|
harm reduction |
4 |
|
hbsag level |
4 |
|
hbv biomarkers |
4 |
|
hbv infection |
4 |
|
hbv transcription |
4 |
|
helicobacter infections/genetics - immunology/microbiology |
4 |
|
helicobacter pylori |
4 |
|
hepatic artery |
4 |
|
hepatitis |
4 |
|
hepatitis b - complications |
4 |
|
hepatitis b - drug therapy - genetics |
4 |
|
hepatitis b - drug therapy - virology |
4 |
|
hepatitis b - immunology - prevention & control |
4 |
|
hepatitis b - pathology |
4 |
|
hepatitis b - transmission |
4 |
|
hepatitis b - virology |
4 |
|
hepatitis b antibodies - blood - immunology |
4 |
|
hepatitis b core antigen |
4 |
|
hepatitis b core antigens - blood |
4 |
|
hepatitis b core antigens - metabolism |
4 |
|
hepatitis b core protein |
4 |
|
hepatitis b genotype |
4 |
|
hepatitis b vaccines - administration & dosage - immunology |
4 |
|
hepatitis b virus - chemistry |
4 |
|
hepatitis b virus - classification - genetics - isolation & purification - pathogenicity |
4 |
|
hepatitis b virus - classification - genetics - isolation and purification |
4 |
|
hepatitis b virus - genetics - isolation & purification |
4 |
|
hepatitis b, chronic - blood - drug therapy - genetics |
4 |
|
hepatitis b, chronic - blood - drug therapy - immunology |
4 |
|
hepatitis b, chronic - classification - diagnosis |
4 |
|
hepatitis b, chronic - complications - drug therapy - ethnology |
4 |
|
hepatitis b, chronic - complications - ethnology - therapy |
4 |
|
hepatitis b, chronic - diagnosis |
4 |
|
hepatitis b, chronic - drug therapy - ethnology - pathology |
4 |
|
hepatitis b, chronic - genetics - metabolism - pathology |
4 |
|
hepatitis b, chronic - metabolism |
4 |
|
hepatitis b, chronic - pathology - physiopathology |
4 |
|
hepatitis b, chronic - physiopathology - virology |
4 |
|
histology |
4 |
|
histone acetylation |
4 |
|
hong kong |
4 |
|
hq-hbsag |
4 |
|
immunization schedule |
4 |
|
immunization, secondary |
4 |
|
immunogenicity |
4 |
|
immunohistochemistry |
4 |
|
immunologic memory |
4 |
|
injections, intra-arterial - methods |
4 |
|
interleukin-1 receptor type 1 knockout mice |
4 |
|
interleukin-1b |
4 |
|
interleukin-1beta/genetics - immunology/metabolism |
4 |
|
interleukin-1β |
4 |
|
iodized oil - administration & dosage |
4 |
|
ip-10 |
4 |
|
isoleucine - genetics |
4 |
|
lamivudine - administration & dosage |
4 |
|
linkage to care |
4 |
|
liver cirrhosis - diagnosis - epidemiology - virology |
4 |
|
liver cirrhosis - pathology |
4 |
|
liver cirrhosis - pathology - physiopathology |
4 |
|
liver cirrhosis - physiopathology - virology |
4 |
|
liver cirrhosis - virology |
4 |
|
liver function tests |
4 |
|
liver neoplasms - diagnosis - virology |
4 |
|
liver neoplasms - mortality - pathology - therapy |
4 |
|
luminescent measurements - methods |
4 |
|
methionine - drug effects - genetics |
4 |
|
microbiota |
4 |
|
mutation, missense - genetics |
4 |
|
necroinflammation |
4 |
|
necrosis - pathology |
4 |
|
neoplasm staging |
4 |
|
nitric oxide |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
placebos |
4 |
|
point of care test |
4 |
|
pwid |
4 |
|
receptors, interleukin-1 type i/genetics - immunology/metabolism |
4 |
|
retrospective studies |
4 |
|
reverse transcriptase inhibitors - administration & dosage |
4 |
|
rna-directed dna polymerase - genetics |
4 |
|
sex distribution |
4 |
|
statistics as topic |
4 |
|
survival rate |
4 |
|
tyrosine - drug effects - genetics |
4 |
|
vaccines, dna - administration & dosage - immunology |
4 |
|
valine - genetics |
4 |
|
viremia - complications |
4 |
|
automation - instrumentation - methods |
3 |
|
bacteriophage m13 - genetics |
3 |
|
complications |
3 |
|
core promoter mutations |
3 |
|
dna primers |
3 |
|
eurohep reference plasma |
3 |
|
hbeag seroreversion |
3 |
|
hbv dna assays |
3 |
|
hbv-dna |
3 |
|
hepatitis b - blood - diagnosis |
3 |
|
hepatitis b - prevention & control |
3 |
|
hepatitis b core antigens - immunology |
3 |
|
hepatitis b e antigens - genetics |
3 |
|
hepatitis b vaccines - administration & dosage |
3 |
|
hepatitis b virus - drug effects - isolation & purification |
3 |
|
hepatitis b virus - genetics - isolation & purification - pathogenicity |
3 |
|
hepatitis b virus - genetics - isolation & purification - physiology |
3 |
|
hepatitis b, chronic - blood - complications |
3 |
|
hepatitis b, chronic - blood - diagnosis |
3 |
|
hepatitis b, chronic - epidemiology - immunology - virology |
3 |
|
hepatitis b, chronic - virology |
3 |
|
hepatocarcinogenesis |
3 |
|
jnj-3989 |
3 |
|
liver cirrhosis - blood - complications - virology |
3 |
|
occult hepatitis b |
3 |
|
pathogenesis |
3 |
|
polymerase chain reaction - methods |
3 |
|
precore mutations |
3 |
|
reagent kits, diagnostic |
3 |
|
rna interference |
3 |
|
sensitivity and specificity |
3 |
|
serum albumin |
3 |
|
angiography |
2 |
|
bare metal stent |
2 |
|
carcinogenesis |
2 |
|
colorectal malignant neoplasm |
2 |
|
estrogen receptor α |
2 |
|
in-stent restenosis |
2 |
|
methylation |
2 |
|
mir-130a |
2 |
|
neoplasm |
2 |
|
nonalcoholic fatty liver disease |
2 |
|
amino acid sequence |
1 |
|
animals |
1 |
|
bacterial adhesion |
1 |
|
bacterial proteins |
1 |
|
bacterial proteins - genetics |
1 |
|
bacterial proteins - genetics - metabolism |
1 |
|
bacterial proteins - genetics - physiology |
1 |
|
base sequence |
1 |
|
cancer-related mortality |
1 |
|
cardiovascular-related mortality |
1 |
|
cell fractionation |
1 |
|
cell line |
1 |
|
cells, cultured |
1 |
|
culture media |
1 |
|
diabetes mellitus |
1 |
|
dna, bacterial - metabolism |
1 |
|
dna, superhelical - chemistry |
1 |
|
dna-binding proteins - genetics - metabolism |
1 |
|
electrophoresis, polyacrylamide gel |
1 |
|
enzyme-linked immunosorbent assay |
1 |
|
epithelial cells - microbiology |
1 |
|
fimbriae proteins |
1 |
|
fimbriae, bacterial - genetics - ultrastructure |
1 |
|
fimbriae, bacterial - physiology |
1 |
|
genes, bacterial |
1 |
|
hegf |
1 |
|
hexosyltransferases - analysis - chemistry - genetics |
1 |
|
immunoblotting |
1 |
|
intestinal mucosa - microbiology |
1 |
|
lac operon |
1 |
|
light-harvesting protein complexes |
1 |
|
lipopolysaccharide |
1 |
|
mafld |
1 |
|
membrane proteins - genetics |
1 |
|
mice |
1 |
|
mice, inbred balb c |
1 |
|
molecular sequence data |
1 |
|
mutagenesis, insertional |
1 |
|
mutagenesis, site-directed |
1 |
|
open reading frames |
1 |
|
operon |
1 |
|
peptides - analysis |
1 |
|
photosynthesis - genetics |
1 |
|
photosynthetic reaction center complex proteins - genetics |
1 |
|
plasmid pslt |
1 |
|
plasmids |
1 |
|
protein biosynthesis |
1 |
|
recombinant fusion proteins - analysis - chemistry - isolation & purification |
1 |
|
rfc |
1 |
|
rhodobacter capsulatus - genetics - growth & development - metabolism |
1 |
|
salmonella typhi - genetics - pathogenicity |
1 |
|
salmonella typhimurium - enzymology - genetics - growth & development |
1 |
|
salmonella typhimurium - genetics |
1 |
|
semi-rough |
1 |
|
sequence homology, amino acid |
1 |
|
serotyping |
1 |
|
transcription factors - genetics |
1 |
|
transcription, genetic |
1 |
|
typhoid fever - etiology |
1 |
|
virulence - genetics |
1 |
|
wzy |
1 |
|
ytl2-incr stabilization |
1 |
